Analyzing non-sentinel axillary metastases in patients with T3–T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy

[1]  G. Plitas,et al.  Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients , 2019, Annals of Surgical Oncology.

[2]  M. Lux,et al.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019 , 2019, Breast Care.

[3]  L. Rydén,et al.  Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases , 2019, BMC Cancer.

[4]  M. Rezai,et al.  Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort , 2019, Breast Cancer Research and Treatment.

[5]  M. Rezai,et al.  Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study , 2019, Annals of Surgical Oncology.

[6]  J. Zhai,et al.  Risk factors and a predictive nomogram for non-sentinel lymph node metastases in Chinese breast cancer patients with one or two sentinel lymph node macrometastases and mastectomy. , 2019, Current oncology.

[7]  G. Plitas,et al.  Abstract PD8-01: Microscopic extracapsular extension in sentinel lymph nodes does not mandate axillary dissection in Z0011-eligible patients , 2019, Poster Discussion Abstracts.

[8]  M. Golatta,et al.  Changes of breast and axillary surgery patterns in patients with primary breast cancer during the past decade , 2018, Archives of Gynecology and Obstetrics.

[9]  M. Lux,et al.  Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer , 2018, Geburtshilfe und Frauenheilkunde.

[10]  G. Nieuwenhuijzen,et al.  The rationale for and long-term outcome of incomplete axillary staging in elderly women with primary breast cancer. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  R. Jagsi,et al.  Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer , 2018, JAMA oncology.

[12]  M. Rezai,et al.  Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice? , 2018, Breast Cancer Research and Treatment.

[13]  R. Gelber,et al.  Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[14]  M. Lux,et al.  Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer , 2018, Geburtshilfe und Frauenheilkunde.

[15]  C. Liedtke,et al.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018 , 2018, Breast Care.

[16]  A. Lal,et al.  Upper limb lymphedema in breast cancer patients in the era of Z0011, sentinel lymph node biopsy and breast conservation , 2018, Irish Journal of Medical Science (1971 -).

[17]  G. Nieuwenhuijzen,et al.  The administration of adjuvant chemo(-immuno) therapy in the post ACOSOG-Z0011 era; a population based study. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  A. Giuliano,et al.  Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial , 2017, JAMA.

[19]  G. Nieuwenhuijzen,et al.  Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era , 2017, Annals of surgery.

[20]  L. Rydén,et al.  Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial , 2017, BMC Cancer.

[21]  G. Phillips,et al.  Healthcare Costs Reduced After Incorporating the Results of the American College of Surgeons Oncology Group Z0011 Trial into Clinical Practice , 2017, The breast journal.

[22]  N. Udvarhelyi,et al.  Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[23]  M. Morrow,et al.  Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review , 2017, JAMA oncology.

[24]  H. Cody,et al.  Extending ACOSOG Z0011 to Encompass Mastectomy: What Happens Without RT? , 2017, Annals of Surgical Oncology.

[25]  E. Brogi,et al.  Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift. , 2016, Archives of pathology & laboratory medicine.

[26]  C. Liedtke,et al.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2016 , 2016, Breast Care.

[27]  M. Shabahang,et al.  Widespread Implications of ACOSOG Z0011: Effect on Total Mastectomy Patients , 2016, The American surgeon.

[28]  D. Dodwell,et al.  POSNOC: A Randomised Trial Looking at Axillary Treatment in Women with One or Two Sentinel Nodes with Macrometastases. , 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

[29]  L. Boersma,et al.  The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07) , 2015, BMC Cancer.

[30]  H. Struikmans,et al.  Regional Nodal Irradiation in Early-Stage Breast Cancer. , 2015, The New England journal of medicine.

[31]  D. Winchester,et al.  Impact of the American College of Surgeons Oncology Group Z0011 Randomized Trial on the Number of Axillary Nodes Removed for Patients with Early-Stage Breast Cancer. , 2015, Journal of the American College of Surgeons.

[32]  R. Mansel,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[33]  S. Apple,et al.  Is Axillary Lymph Node Dissection Necessary After Sentinel Lymph Node Biopsy in Patients with Mastectomy and Pathological N1 Breast Cancer? , 2014, Annals of Surgical Oncology.

[34]  Maureen A. Smith,et al.  Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on Clinical Management of the Axilla in Older Breast Cancer Patients: A SEER-Medicare Analysis , 2013, Annals of Surgical Oncology.

[35]  A. Luini,et al.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. , 2013, The Lancet. Oncology.

[36]  U. Güth,et al.  The post ACOSOG Z0011 era: does our new understanding of breast cancer really change clinical practice? , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[37]  A. Giuliano,et al.  To Cut Is to Cure: Can We Really Apply Z11 in Practice? , 2011, Annals of Surgical Oncology.

[38]  T. Julian,et al.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. , 2010, The Lancet. Oncology.

[39]  Kelly K. Hunt,et al.  Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. , 2010, Annals of surgery.

[40]  Andreas Schneeweiss,et al.  Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Brucker,et al.  Onkologische Qualitätssicherung am Beispiel des Mammakarzinom-Benchmarkings interdisziplinärer Brustzentren , 2008 .

[42]  Umberto Veronesi,et al.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.

[43]  A. Giuliano,et al.  Proceedings of the Consensus Conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania , 2002, Cancer.

[44]  Umberto Veronesi,et al.  Proceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast April 19–22, 2001, Philadelphia, PA, USA , 2002 .

[45]  T. Whelan,et al.  Regional Nodal Irradiation in Early-Stage Breast Cancer. , 2015, The New England journal of medicine.

[46]  Bingshu E. Chen,et al.  Regional Nodal Irradiation in Early-Stage Breast Cancer. , 2015, The New England journal of medicine.

[47]  H. Kuerer,et al.  Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. , 2013, Journal of the American College of Surgeons.